Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Wave Life Sciences Ltd.NASDAQ: WVE

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $69.54M rose 22.4% year over year, ahead of the +15.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Operating expenses amounted to 583.4% of revenue in FY2025, up 381.4 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.4% holds above the trailing-twelve-month pace of +15.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$69.54M-2.7% QoQ
Last fiscal yearDec 2025
$249.26M+14.0% YoY
LTMMar 2026
$264.22M+15.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.4%——
1 year+14.0%——
3-year CAGR+14.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
249.26M USD
Year-over-year change
+14.0%
4-year CAGR
+10.4%

Operating Expenses vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.6% is the 6th highest of 10, against a peer median of +22.3%.
  • Operating expenses amounts to 368.0% of revenue for WVE, versus a peer median of 287.9%.
WVE Competitors
Operating Expenses for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$2.83B USD+26.4%+15.3%58.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$1.51B USD+22.3%+10.0%157.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$1.4B USD-27.8%+14.1%64.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.16B USD+58.1%+38.7%256.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$319.11M USD-10.9%-0.7%482.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$264.22M USD+15.6%+14.4%368.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$214.24M USD+41.4%+20.6%667.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$130.57M USD-39.9%-10.4%287.9%
SLNSilence Therapeutics plcLTM Mar 2026$87.2M USD—+16.9%9463.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026€58.51M EUR+12.1%-7.3%435.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026$53.82M USD+43.6%+32.6%—
Peer median (excluding WVE) —+22.3%+14.7%287.9%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.